SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

Home・Akcijų sąrašas・Vetoquinol SA

Vetoquinol SA

Uždarymo kaina

SektoriusSveikatos priežiūra

84.7 0.36

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

83.8

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	25M
Pardavimai	258M
P/E Sektoriaus vid.	16.706 108.767
Dividendų pajamingumas	1.03
Pelno marža	9.734
Darbuotojai	2,497
EBITDA	48M

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.03% 2.21%
Kitas uždarbis	2026-03-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B
Ankstesnė atidarymo kaina	84.34
Ankstesnė uždarymo kaina	84.7

Naujienos nuotaikos

By Acuity

50%

167 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

72.6 / 75.1 Palaikymas ir pasipriešinimas

Vetoquinol SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-25 23:25; UTC

Karštos akcijos

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026-02-25 23:15; UTC

Uždarbis

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026-02-25 23:54; UTC

Rinkos pokalbiai

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026-02-25 23:47; UTC

Uždarbis

Ferrovial 4Q Net EUR197M >FER.MC

2026-02-25 23:45; UTC

Uždarbis

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026-02-25 23:42; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026-02-25 23:38; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Company's Business Operations Remain Normal >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY EPS CNY47.67 >TCOM

2026-02-25 23:06; UTC

Uždarbis

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026-02-25 23:01; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026-02-25 23:00; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-02-25 23:00; UTC

Rinkos pokalbiai

Uždarbis

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026-02-25 22:56; UTC

Rinkos pokalbiai

Uždarbis

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026-02-25 22:43; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026-02-25 22:40; UTC

Rinkos pokalbiai

Uždarbis

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026-02-25 22:40; UTC

Uždarbis

Karoon Energy Says Search for New CFO Well Advanced

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says CFO Ray Church to Leave Company

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026-02-25 22:38; UTC

Uždarbis

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Akcijų palyginimas

Kainos pokytis

Vetoquinol SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Vetoquinol SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

72.6 / 75.1Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

167 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.